1. Information about this Guideline – Prostate Cancer
1.1 Editors
The German Guideline Program in Oncology (GGPO) organized by the Association of the Scientific Medical Societies (AWMF), the German Cancer Society (DKG) and the German Cancer Aid (DKH).
1.2 Leading Scientific Societies
Deutsche Gesellschaft für Urologie (DGU)
1.3 Funding of the Guideline
This guideline was sponsored by the German Cancer Aid within the framework of the German Guideline Program in Oncology.
1.4 Contact
German Guideline Program in Oncology
Office c/o German Cancer Society
Kuno-Fischer St. 8
D-14057 Berlin
leitlinienprogramm@krebsgesellschaft.de
www.leitlinienprogramm-onkologie.de
1.5 How to cite
Leitlinienprogramm-Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostate Cancer, Langversion 6.2, 2021, AWMF-Registernummer 043/022OL, https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
1.6 Previous Changes of Version 6.2
October 2021, Version 6.2: Specification of the comment on quality indicator 12 (Focal therapy for locally-advanced prostate cancer) regarding focal stereotactic radiation.
July 2021, Version 6.1: Addition of updated quality indicators, revision of Recommendation 7.10 (addition of bicalutamide), correction of information regarding the ARAMIS study (background text Recommendation 7.32).
1.7 Special Comment
The field of medicine is subject to a continuous process of further development, so that all details provided here, and in particular those on diagnostic and therapeutic procedures, can always only represent the state of knowledge at the time when the medical care guideline was printed. The greatest possible care has been taken with regard to the treatment recommendations given and to the choice and dosage of drugs. However, users are requested to check by referring to the patient package inserts and specialist information provided by the manufacturers, and in cases of doubt to consult a specialist. In the general interest of the guideline editors, readers are requested to draw attention to any questionable points or inconsistencies found.
Users themselves remain responsible for all diagnostic and therapeutic applications, medications, and dosages.
Registered trademarks (protected proprietary names) are not specially identified in this guideline. The absence of an indication of this type can therefore not be taken to suggest that such names are unregistered product names.
All parts of this guideline are protected by copyright. Any usage outside of the provisions of copyright law without written permission from the German Guideline Program in Oncology editors is therefore unlawful and liable to prosecution. No part of this work may be reproduced in any form without written permission from the German Guideline Program in Oncology editors. This applies in particular to reproduction, translation, microfilming and storage, usage and exploitation in electronic systems, intranets and the Internet.
1.8 Objectives of the GGPO
The aim of the Association of the Scientific Medical Societies in Germany (AWMF), the German Cancer Society (DKG), and the German Cancer Aid Foundation (Stiftung Deutsche Krebshilfe) in implementing the German Guideline Program in Oncology (GGPO) is to jointly promote and support the development, updating, and use of scientifically based and practicable guidelines in oncology. The program is based on medical and scientific findings established by the specialist societies and the DKG, consensus among medical experts, users and patients, as well as the AMWF's regulations for guideline development. The program receives specialist support and financing from the German Cancer Aid. In order to reflect the current state of medical knowledge and to take account of medical progress, guidelines have to be regularly checked and updated. The use of the AWMF regulations is intended to provide a basis for developing of high-quality oncological guidelines in this framework. As guidelines represent an important instrument for quality assurance and quality management in oncology, they are intended to be used in a targeted and sustained way in everyday medical care. Active implementation measures and also evaluation programs are therefore important components of the support provided by the German Guideline Program in Oncology. The aim of the program is to create professional preconditions, with secure medium-term financing, for the development and provision of high-quality guidelines in Germany. High-quality guidelines of this type not only serve for structured knowledge transfer but can also be used in the design of health-care structures. Relevant aspects of this include evidence-based guidelines as a basis for establishing and updating disease management programs, and the use of quality indicators derived from guidelines in the context of certification procedures for organ tumor centers.
1.9 Additional Documents relating to this Guideline
This document is the long version of the S3 guideline on prostate cancer, which can be accessed via the following pages
- German Guideline Program in Oncology (https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/)
- AWMF (www.awmf.org/leitlinien/aktuelle-leitlinien.html)
- Guidelines International Network (www.gin.net)
In addition to the long version, the following supplementary documents are available:
- Guideline Report on the guideline
- Document with the evidence report on the guideline report
- Short version of the guideline
- Patient guideline "Early detection of prostate cancer"
- Patient guideline "Prostate cancer 1 - Localized prostate cancer"
- Patient guideline "Prostate Cancer 2 - Locally Advanced and Metastatic Prostate Cancer"
The guideline is also included in the German Guideline Program in Oncology app.
More informationis available at: https://www.leitlinienprogramm-onkologie.de/app/
1.10 Composition of the Guideline Group
1.10.1 Coordination and Reaction
Guideline steering group
Marc-Oliver Grimm (chairman), Manfred Wirth (Sprecher), Dirk Böhmer, Christian Bolenz, Michael Fröhner, Peter Jürgen Goebell, Oliver Hakenberg, Thomas Wiegel, Bernhard Wörmann.
1.10.2 Involved Professional Societies and Organisations
The medical societies and other organizations involved in the guideline update and their mandated representatives are listed in the table below. More detailed information on the participants of the previous versions can be found in the documentation history (https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/).
Table 1: Beteiligte Fachgesellschaften und Organisationen
Beteiligte Fachgesellschaften und Organisationen
| Beteiligte Fachgesellschaften und Organisationen | Mandatsträger/beteiligte Experten |
| Deutsche Gesellschaft für Radioonkologie (DEGRO) | Prof. Dr. Daniel Aebersold, Prof. Dr. Nina-Sophie Schmidt-Hegemann, Prof. Dr. Felix Sedlmayer, Prof. Dr. Thomas Wiegel |
| Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) | Prof. Dr. Ulrich Kaiser, Prof. Dr. Gunhild von Amsberg, Prof. Dr. Bernhard Wörmann |
| Deutsche Gesellschaft für Palliativmedizin (DGP) | Dr. Christina Gerlach, Prof. Dr. Björn Volkmer |
| Deutsche Gesellschaft für Nuklearmedizin (DGN) | Prof. Dr. Ali Afshar-Oromieh, Prof. Dr. Matthias Eiber, Prof. Dr. Bernd Krause, Prof. Dr. Kambiz Rahbar, Prof. Dr. Matthias Schmidt |
| Deutsche Gesellschaft für Geriatrie (DGG) | Prof. Dr. Andreas Wiedemann, PD Dr. Ulrich Wedding |
| Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) | Prof. Dr. Thomas Kötter, Dr. Til Uebel |
| Berufsverband der Deutschen Urologie (BvDU) | Prof. Dr. Peter Jürgen Goebell |
| Berufsverband Deutscher Strahlentherapeuten (BVDST) | Dr. Clemens Albrecht, Prof. Dr. Pirus Ghadjar, Prof. Dr. Peter Niehoff, Prof. Dr. Michael Pinkawa, Prof. Dr. Daniel Zips |
| Berufsverband der Deutschen Radiologie (BDR) | Prof. Dr. Patrick Asbach |
| Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie in der DKG (AGSMO) | Prof. Dr. Freerk Baumann, Dr. Wilfried Hoffmann |
| Berufsverband Deutscher Strahlentherapeuten (BVDST) | - 2013-2018 |
| Arbeitsgemeinschaft für Psychoonkologie in der DKG (PSO) | Dr. Dominik Fugmann, Dr. André Karger |
| Arbeitsgemeinschaft Prävention und integrative Medizin in der Onkologie in der DKG (PRiO) (PRIO) | Prof. Dr. Oliver Micke, PD Dr. Thorsten Schmidt |
| Arbeitsgemeinschaft Radiologische Onkologie in der DKG (ARO) | Prof. Dr. Dirk Böhmer, Prof. Dr. Michael Flentje, Prof. Dr. Arndt-Christian Müller, Prof. Dr. Stefan Höcht |
| Arbeitsgemeinschaft Onkologische Rehabilitation und Sozialmedizin in der DKG (AGORS) | Dr. Wilfried Hoffmann |
| Arbeitsgemeinschaft Urologische Onkologie der Deutschen Krebsgesellschaft (AUO) | Prof. Dr. Markus Graefen, Prof. Dr. Peter Hammerer |
| Bundesverband Prostatakrebs Selbsthilfe (BPS) | Hans-Josef Beckers, Ernst-Günther Carl, Josef Dietz, Udo Ehrmann, Dipl.Ing. Paul Enders, Dipl. Ing. Jens-Peter Zacharias |
| Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL) | Prof. Dr. Stefan Holdenrieder |
| Deutsche Gesellschaft für Pathologie (DGP) | Prof. Dr. Arndt Hartmann, Prof. Dr. Glen Kristiansen, Prof. Dr. Wilfried Roth |
| Berufsverband Deutscher Pathologinnen und Pathologen (BDP) | Prof. Dr. Arndt Hartmann, Prof. Dr. Glen Kristiansen, Prof. Dr. Wilfried Roth |
| Deutsche Gesellschaft für Urologie (DGU) | Prof. Dr. Peter Albers, Prof. Dr. Andreas Blana, Prof. Dr. Christian Bolenz, Prof. Dr. Angelika Borkowetz, Prof. Dr. Martin Burchardt, Prof. Dr. Maximilian Burger, Prof. Dr. med. habil. Michael Fröhner, Prof. Dr. Christian Gratzke, Prof. Dr. Boris Hadaschik, Prof. Dr. Oliver Hakenberg, Prof. Dr. Axel Heidenreich, Dr. Thomas-Oliver Henkel, Prof. Dr. Tillmann Loch, Prof. Dr. Gerd Lümmen, Dr. Stefan Machtens, Prof. Dr. Ullrich Otto, Prof. Dr. Karl Pummer, Prof. Dr. Martin Schostak, Prof. Dr. Axel Semjonow, Prof. Dr. Stefan Siemer, Prof. Dr. Dr. Arnulf Stenzl, Prof. Dr. Thomas Steuber, Dr. Sigrid Wagner, Prof. Dr. Friedhelm Wawroschek, Prof. Dr. Dr. Manfred P. Wirth, Prof. Dr. Johannes M. Wolff, PD Dr. Stefan Zastrow, Prof. Dr. Marc-Oliver Grimm, Prof. Dr. Carsten-Henning Ohlmann |
| Deutsche Röntgengesellschaft (DRG) | Prof. Dr. Dirk Beyersdorff, Prof. Dr. Lars Schimmöller, Prof. Dr. Tobias Franiel, Prof. Dr. Dipl.-Phys. Heinz-Peter Schlemmer |
| undefined | Prof. Dr. Roman Ganzer, PD Dr. Tobias Penzkofer, PD Dr. Jan-Philipp Radke |
| als Experte ad personam | Prof. Dr. Roman Ganzer, PD Dr. Hannes Cash, PD Dr. Tobias Penzkofer, PD Dr. Jan-Philipp Radke |
| Konferenz Onkologischer Kranken- und Kinderkrankenpflege in der DKG (KOK) | Kerstin Paradies |
.
1.10.3 Other Patient Involvement (without voting rights)
1.10.4 Patient Involvement
Representatives (Beckers, Carl, Dietz, Ehrmann, Enders, Zacharias) of the Federal Society for Prostate Cancer Self-Help (Bundesverbandes Prostatakrebs Selbsthilfe, BPS) were involved in the creation of and the voting on recommendations during the entire development process of the guideline and its later updates.
1.10.5 Methodological Support
- German Agency for Quality in Medicine (ÄZQ), a joint institution of the German Medical Association (BÄK) and the National Association of Statutory Health Insurance Physicians (KBV): Katrin Krueger, Corinna Schaefer
- Association of the Scientific Medical Societies in Germany (AWMF): Prof. Dr. med. Ina Kopp; Dr. med. Monika Nothacker, MPH
- German Guideline Program in Oncology, GGPO: Dr. med. Markus Follmann, MPH, MSc; Dipl.-Soz. Wiss. Thomas Langer
- UroEvidence: Dr. Stefanie Schmidt, MPH
- University Hospital Jena: Dr. Katharina Leucht
More detailed information on previous versions of the guideline can be found in the documentation history (https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/).